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L E T T E R T O TH E E D I T O R
Comment on the article by Eshetie et al. entitled “Potentially
inappropriate medication use and related hospital admissions
in aged care residents: The impact of dementia”
Dear Editor,
We really appreciated the work by Eshetie et al1 who analysed
the prevalence of potentially inappropriate medications (PIMs)
according to the 2019 AGS Beers and 2015 STOPP criteria at admis-
sion and at discharge in 181 patients aged ≥75 years with polytherapy
(mean drugs at admission 10) and discharged to residential care
facilities, stratified according to history of cognitive impairment. This
study showed, once more, the high burden of inappropriate prescrib-
ing (IP) in daily clinical practice, recording an extremely high preva-
lence of STOPP PIMs at discharge irrespective of presence or absence
of dementia (79.1% vs. 85.6%, respectively), without significant
changes during hospital admission. Moreover, a possible or probable
PIM-related hospitalization was recorded in 45 patients (24.9%) at
admission, in 75.6% of cases involving STOPP PIMs. The authors
report conflicting results of previous studies on the impact of hospital
admission on PIM prevalence, including a Spanish cohort study on
200 patients discharged from an acute geriatric ward (GW) that did
not demonstrate a change in PIM use.1
At this regard, we would like to report the results of two papers
we recently published on this topic, investigating the prevalence and
clinical implications of polypharmacy and IP among patients aged
≥65 years discharged from three internal medicine wards (IMWs) and
two GWs of two tertiary hospitals in North-western Italy.2,3 In the
cross-sectional part of the study, we investigated the prevalence of,
and factors associated with, PIMs and potential prescribing omissions
(PPOs) identified at discharge according to 2015 STOPP/START
criteria.2 Every patient underwent a multidimensional assessment,
including standardized scales for frailty, cognitive impairment, func-
tional status, and comorbidity. We collected a sample of 726 patients
(mean age 81.5 years, 36% discharged to medium/long-term care
facilities, MLTCFs) with a high burden of comorbidities and geriatric
syndromes (28.5% had moderate to severe cognitive impairment).2
Table 1 compares principal characteristics of our sample2 and that by
Eshetie et al1; because of less stringent inclusion criteria, our sample
was generally younger and presumably had better overall health sta-
tus, resulting in a lower number of prescribed medications (mean 7.5
vs. 11) and a lower prevalence of STOPP PIMs (54.4% vs. 82.3%) at
discharge. However, this gap significantly narrows when considering
patients with hyperpolypharmacy, that presented a 74.4% STOPP
PIM prevalence in our sample.2 Indeed, at multivariate analysis, a
higher number of drugs at discharge was associated with presence of
at least one STOPP PIM (OR 1.22, 95% CI 1.15–1.28), whereas GW
discharge was protective (OR 0.55, 95% CI 0.40–0.75). The same
associations were recorded also for PPOs.2
Even if we did not perform a formal analysis on prescribing trends
during hospital stay, it is interesting to note that, while the mean
number of drugs at admission was superimposable in patients from
IMWs and GWs (6.8 ± 3.5 vs. 6.3 ± 3.2), IMW-discharged patients
showed a significantly higher number of drugs than GW-discharged
ones (8.2 ± 3.3 vs. 6.9 ± 2.9), as well as higher prevalence of PIMs
(63.8% vs. 45.1%) and PPOs (53.9% vs. 35.2%).2 Several factors may
contribute to these findings, including the recognized experience of
geriatricians in older patients' prescribing recommendations. Another
option could be the higher prevalence of patients with dementia
observed in GWs in our sample2; in the work by Esethie et al., patients
with dementia had lower STOPP PIM prevalence than subjects
without dementia (83.5% vs. 93.3%).1
In the prospective part of our study, we evaluated whether PIMs
and PPOs were associated with 6-month mortality and unplanned
hospitalization in the overall sample, and according to discharge set-
ting, excluding terminally ill patients.3 Among 611 patients studied,
25.0% died and 30.9% were readmitted at least once. Not unexpect-
edly, mortality was higher in MLTCF-discharged patients (32.1%
vs. 21.4%), while rehospitalization rates were lower (24.4% vs. 34.3%).
Neither PIMs nor PPOs were associated with mortality, while a higher
number of STOPP PIMs was independently associated with
readmissions in the overall sample (OR 1.23, 95% CI 1.03–1.46) and
in home-discharged patients (OR 1.38, 95% CI 1.13–1.68). Among
MLTCF-discharged patients, a higher drug burden (OR 1.27, 95% CI
1.13–1.42) and neurological comorbidities (excluding dementia) were
associated with unplanned readmission.3 The lack of an association
between STOPP PIMs and rehospitalizations in MLTCF-discharged
patients might be due to local management of prescriptions and
adverse events.
The main strength of our study is its prospective design and the
systematic use of standardized scales, which reduces the bias inherent
to the retrospective collection of information derived from real-world
clinical practice and allows to correct for the potential confounding
effect of geriatric syndromes. Yet, some potential limitations should
be discussed. First, the prevalence of STOPP PIMs could be over-
estimated both in our study2,3 and in that by Eshetie et al1 because
the use of STOPP criteria in very old people with geriatric syndromes,
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2 LETTER TO THE EDITOR
multimorbidity and polypharmacy may induce a high number of PIMs
that the geriatrician in charge may consider irrelevant for the single
patient. In recent years, several criteria were suggested for use in vul-
nerable patients, including the STOPPFrail, recently updated.4 Despite
their name, these criteria were developed for use in older patients
approaching the end of life, with the main goal to reduce drug-related
morbidity and burden without compromising health or quality of life.4
Their application requires careful evaluation of end of life status
(target patients typically meet all the following: functional dependency
and/or severe chronic disease and/or terminal illness; severe irrevers-
ible frailty; high risk of acute medical complications and clinical
deterioration; death in the following 12 months not surprising)4; thus,
STOPPFrail were not evaluated in either study.1–3
Our study might have been underpowered to identify a direct
relationship between PIMs and cause of admission, also considering
that STOPP PIMs were responsible of just 18.8% of total hospitaliza-
tions in the sample of institutionalised older patients studied by
Eshetie et al.1
Even if interventions on PIM recognition and reconciliation are
meant to reduce drug-related hospital admissions, we could demon-
strate only an association with reduced all-cause hospitalization in the
overall sample and in home-discharged patients. In real-world older
patients with multiple chronic conditions, it may be extremely
challenging to identify a direct causal association between PIMs and
unplanned readmissions, and this rigorous methodological approach
would probably underestimate the potential clinical benefit of PIM
reduction. Indeed, multiple concurring factors intervening in a short
period of time may make it difficult to trace back the first pharmaco-
logical harm that triggered the sequence of events leading to hospitali-
zation. Therefore, even if the lower hospitalization rate in patients
without STOPP PIMs we observed in our study cannot be fully
ascribed to reduced drug-related hospital admissions, these findings
maintain some clinical relevance, demonstrating once more that adher-
ence to well-acknowledged criteria of appropriate prescribing in older
subjects is associated with overall clinical benefit. In accordance with
previous studies,5–9 and combining the strengths of our work (i.e., a
large sample size and correction for important prognostic variables)2,3
with the proof of a direct implication of PIMs in hospital admission by
Eshetie et al1 there is a strong rationale that reducing polypharmacy
and IP may reduce hospitalizations in vulnerable older patients. The
results of recently concluded randomized clinical trials10,11 will help
clinicians to disentangle the impact of STOPP PIM reduction on
hard clinical outcomes, including drug-related admissions.
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